Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition

18 Jun 2014

Abstract excerpt

// Ilaria Passacantilli 1,2 , Gabriele Capurso 2 , Livia Archibugi 2 , Sara Calabretta 1,2 , Sara Caldarola 3 , Fabrizio Loreni 3 , Gianfranco Delle Fave 2 and Claudio Sette 1,4 1 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy 2 Digestive & Liver Disease Unit, University of La Sapienza, Rome, Italy 3 Department of Biology, University of Rome Tor Vergata, Rome, Italy 4...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neuroendocrine Tumor Research Advances
Share to Pancreatic and Hepatic Oncology Research
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25026292
DOI: 10.18632/oncotarget.2111

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 26 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibitionPMID 25026292Read ↗

RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor GrowthSemantic proximity Read ↗

Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1Semantic proximity Read ↗

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivationSemantic proximity Read ↗

Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.Semantic proximity Read ↗

Mechanisms of resistance to rapamycins.Semantic proximity Read ↗

Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.Semantic proximity Read ↗

mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular CarcinomaSemantic proximity Read ↗

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances the Antitumoral Activity of Gemcitabine in Human Pancreatic Cancer Cell LinesSemantic proximity Read ↗

Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer.Semantic proximity Read ↗

Reversing Drug Resistance In VivoSemantic proximity Read ↗

K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.Semantic proximity Read ↗

Bi-steric mTORC1-selective Inhibitors activate 4EBP1 reversing MYC-induced tumorigenesis and synergize with immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.